Introduction
============

Colorectal carcinoma (CRC) is the second most prevalent cancer worldwide.[@b1-cmar-10-3875] Most CRCs arise through the adenoma--carcinoma sequence, which takes, on average, 10--20 years to develop; this fact alone makes the screening and prevention of CRCs by colonoscopic examination and polypectomy feasible.[@b2-cmar-10-3875] Advanced colorectal adenomas (ACAs; adenoma ≥10 mm or ≥25% villous features, or high-grade dysplasia), proposed by Atkin et al in 1992, are considered to be dangerous, precancerous lesions.[@b3-cmar-10-3875] In the past 2 decades, the prevalence of ACAs has steadily increased.[@b4-cmar-10-3875]--[@b6-cmar-10-3875] It shows that the prevalence of ACAs has great relevance regarding a patient's indications for a colonoscopy and that other factors, such as age, sex, and diet, could not be neglected.[@b7-cmar-10-3875]--[@b9-cmar-10-3875] In many studies, the indications, such as screening, surveillance, or symptoms, had been taken into account.[@b5-cmar-10-3875]--[@b7-cmar-10-3875] There is still paucity of data to investigate the prevalence of ACAs when the three indications are analyzed at one time. Moreover, the distribution of ACAs, stratified by location and morphology of colorectal lesions, has not yet been extensively investigated. The risk of an adenoma becoming malignant or CRC is the greatest for ACAs, highlighting the importance of identifying adenoma patients with high risk for close surveillance after initial polypectomy. Therefore, we designed a cross-sectional study of local patients, so that the prevalence and distribution of ACAs could be assessed.

Materials and methods
=====================

Study population
----------------

Patients who were consecutively enrolled in the study were referred to receive a colonoscopy after obtaining written informed consent documentation. The study subjects were divided into three groups referred to as the screening subgroup, the surveillance subgroup, and the symptomatic subgroup, according to their indications. Asymptomatic patients were those who underwent a colonoscopy as a precautionary measure to screen for colorectal cancer (CRC) (the screening subgroup), as well as those who had a surveillance colonoscopy for having a medical history of colorectal neoplasm or a family history of CRC in a first-degree relative (the surveillance subgroup). Symptomatic patients (the symptomatic subgroup) were those who experienced hematochezia, melena, diarrhea, constipation, anemia, weight loss, or abdominal pain. The symptomatic patients were then further divided into two groups. The patients in alarm symptomatic category experienced anemia, hematochezia, melena, or weight loss, and the patients in non-alarm symptomatic category experienced constipation, diarrhea, or abdominal pain.

For inclusion in the study, subjects were required to have undergone a colonoscopy for screening, surveillance, or symptomatic. Exclusion criteria for the study subjects were as follows: having undergone a previous surgical resection of any part of the colon; having a history of CRC, inflammatory bowel disease, polyposis syndrome, or hereditary nonpolyposis colon cancer; being in poor physical condition; and insufficient bowel preparation. The study protocol was approved by the institutional ethical committee of the Second Affiliated Hospital of Nantong University (China) and was in accordance with the revised Helsinki Declaration of 1983.

Patients received an orally administered glucose--electrolyte solution containing polyethylene glycol 4--6 hours before the examination. All colonoscopies were performed by an expert endoscopist using a high-resolution Olympus endoscope (CF-H260AZL; Olympus, Tokyo, Japan).

The size, location, and morphology of all lesions were recorded. The sizes of the lesions were visually estimated using standard biopsy forceps. The distal colon was defined as the rectum, the sigmoid colon, and the descending colon, which also included the splenic flexure. Similarly, the proximal colon was defined as the transverse colon, the ascending colon, and the cecum. This information is based on the standard classification system described by the Paris endoscopic classification of superficial neoplastic lesions.[@b10-cmar-10-3875] The morphology of colorectal lesions was divided into polypoid and nonpolypoid types. The former consists of pedunculated (0-Ip), semipedunculated (0-Isp), and sessile (0-Is) lesions, and the latter consists of slightly elevated (0-IIa), completely flat (0-IIb), and slightly depressed (without ulcer; 0-IIc) lesions.

All identified lesions were removed via biopsy, endoscopic resection (polypectomy, endoscopic mucosal resection, and endoscopic submucosal dissection), or conventional surgery for histological evaluation. The pathologist independently identified the colorectal lesions, according to the Vienna classification of gastrointestinal epithelial neoplasm, without oral or written communication with the endoscopist.[@b11-cmar-10-3875] ACAs can be defined as the presence of adenomas that are ≥10 mm in size, have more than 25% villous features, and have high-grade dysplasia.[@b3-cmar-10-3875] The ACAs included in this study were defined by experienced endoscopists and pathologists.

Statistical analysis
--------------------

Statistical analysis was performed with SPSS software (version 16.0; SPSS Inc, Chicago, IL, USA). Continuous variables were summarized as mean and SD. Categorical variables were summarized using percentages, and 95% CIs were calculated. Continuous variables were compared using the Student's *t*-test or ANOVA. Categorical data were compared to the Pearson chi-squared test or the Fisher's exact test. The OR indicated a 95% CI. Differences were considered significant if the two-tailed *P*-value was \<0.05.

Results
=======

Between July 2009 and June 2011, a total of 2,876 patients were enrolled in the study, and they underwent colonoscopies that were performed by an experienced endoscopist. However, 66 patients did not complete the entire colonoscopy. The cecal intubation process was completed in 2,810 cases (97.7% of the time). Of these 2,810 patients, 565 were in the screening subgroup, 813 were a part of the surveillance subgroup, and 1,432 were in the symptomatic subgroup. Overall, 514 patients were in the alarm symptomatic category, and 918 patients were in the non-alarm symptomatic category. Moreover, 869 patients with 1,342 colorectal lesions were detected in the complete cohort, including 57 cases of advanced carcinoma. Finally, 1,285 colorectal lesions were analyzed in total. The target population demographics are depicted in [Table 1](#t1-cmar-10-3875){ref-type="table"}, and the clinicopathological features of the 1,285 colorectal lesions are indicated in [Table 2](#t2-cmar-10-3875){ref-type="table"}.

As listed in [Table 3](#t3-cmar-10-3875){ref-type="table"}, the prevalence of ACAs in patients who underwent colonoscopies for screening, surveillance, and\\symptoms was 4.1% (95% CI, 2.5%--5.7%; n=565), 4.6% (95% CI, 3.2%--6.0%; n=813), and 11.0% (95% CI, 9.4%--12.6%; n=1,432), respectively. There were significantly more patients with ACAs in the symptomatic subgroup than in the screening or the surveillance subgroup (11.0% vs 4.1%, *P*\<0.001; 11.0% vs 4.6%, *P*=0.006). In the surveillance subgroup, the prevalence of ACAs was found to be 4.6%; therefore, no statistical significance was concluded compared to the screening subgroup (4.6% vs 4.1%, *P*=0.346).

In the symptomatic subgroup, 68 of the patients were found to have 79 ACAs in the alarm category, and 89 of the patients were found to have 105 ACAs in the non-alarm category. The prevalence of ACAs in the alarm and non-alarm categories was 11.7% (95% CI, 8.9%--14.5%; n=514) and 9.7% (95% CI, 7.8%--11.6%; n=918), respectively. There was no statistical significance between the two groups (11.7% vs 9.7%, *P*=0.056).

The distribution of colorectal lesions and ACAs, stratified by location and morphology of the subgroups, is listed in [Table 4](#t4-cmar-10-3875){ref-type="table"}. Furthermore, [Tables 5](#t5-cmar-10-3875){ref-type="table"} and [6](#t6-cmar-10-3875){ref-type="table"} list the proportion of ACAs in colorectal lesions stratified by location and morphology.

In the symptomatic subgroup, distal lesions were more likely to contain ACAs than proximal ones (OR 1.50, 95% CI 1.05--2.15, *P*=0.024); however, no significant results were revealed in the screening subgroup (OR 0.66, 95% CI 0.37--1.38, *P*=0.322) or in the surveillance subgroup when comparing the likelihood of occurrence of ACAs (OR 0.60, 95% CI 0.31--1.18, *P*=0.139). The proportion of ACAs in the distal lesions was 24.4% (95% CI 20.8%--28.0%) in the symptomatic subgroup, 13.1% (95% CI 7.5%--18.7%) in the screening subgroup, and 15.4% (95% CI 9.2%--21.6%) in the surveillance subgroup. There were significantly more ACAs in the distal lesions of a part of the symptomatic subgroup, compared to their prevalence in the screening subgroup (24.4% vs 13.1%, *P*=0.005) or surveillance subgroup (24.4% vs 15.4%, *P*=0.028).

Nonpolypoid lesions with higher proportions of ACAs were also found in the symptomatic subgroup (OR 2.09, 95% CI 1.48--2.94, *P*\<0.001), but no significant difference was detected in the screening subgroup (OR 1.93, 95% CI 0.92--4.02, *P*=0.078) or the surveillance subgroup (OR 0.61, 95% CI 0.31--1.23, *P*=0.165). The proportion of ACAs in the nonpolypoid lesion category was 31.5% (95% CI, 25.5%--37.5%) in the symptomatic subgroup, 20.2% (95% CI, 12.1%--28.3%) in the screening subgroup, and 14.7% (95% CI, 7.8%--21.6%) in the surveillance subgroup. A higher proportion of ACAs were categorized as nonpolypoid lesions in the symptomatic subgroup compared to the screening subgroup (31.5% vs 20.2%, *P*=0.041) or surveillance subgroup (31.5% vs 14.7%, *P*=0.001).

Discussion
==========

The incidence and distribution data of ACAs described in this report identify several priority areas for CRC prevention. First, the incidence of ACAs was higher in the symptomatic subgroup compared to that in the screening or surveillance subgroups and should be the focus for prevention. We also report high rates of distal lesions and nonpolypoid lesions in the symptomatic subgroup, indicating an important target for CRC prevention.

The incidence of ACAs and CRCs is increasing rapidly in both Asian and Western populations.[@b11-cmar-10-3875] The high-risk factors for colorectal tumor in these populations are believed to be different, but the details are not yet known. Prior to our study, two previous studies focused on the prevalence of ACAs in a target group of asymptomatic Chinese subjects. Sung et al[@b5-cmar-10-3875] enrolled 505 subjects in health exhibitions who were ≥50 years old and documented 12.5% of ACAs in a population of Hong Kong Chinese subjects. Another group of researchers, Liu et al,[@b6-cmar-10-3875] detected 3.3% of ACAs in a group of asymptomatic Taiwanese Chinese subjects. In this study, 4.1% of ACAs were detected among 565 asymptomatic subjects in mainland China. The high prevalence of ACAs in the first target subject groups may in part reflect the relatively large number of individuals who were older (\>50 years old). In addition, as shown in [Table 1](#t1-cmar-10-3875){ref-type="table"}, an inherent selection bias in terms of enrolled subjects, geography (mostly from urban areas), or dietary factors were among other plausible explanations.

Unlike previous studies that only examined asymptomatic subjects, this study also focuses on surveillance and symptomatic patients who might have a higher likelihood of having colorectal neoplasms. Subjects in the surveillance group showed a 4.6% prevalence for ACAs, with no significant differences compared to the screening subgroup. This result suggests that ACAs do progress to invasive cancer and that understanding the epidemiology of ACAs would predict the risk of CRC. Similarly, Costedio et al[@b12-cmar-10-3875] note that family history does not predict an increase in ACAs. However, research by Armelao et al[@b7-cmar-10-3875] indicates that patients having first-degree relatives with CRC hold an increased risk of ACAs compared to average-risk individuals.

Nevertheless, the prevalence of ACAs among patients in the symptomatic subgroup was 11.0%, which is significantly higher than that among patients in the screening or surveillance subgroup; this statistic corresponds with the results of a prior study conducted by Soetikno et al.[@b13-cmar-10-3875] In another study, the prevalence of advanced neoplasms (including ACAs and cancer) was 9.4% in a total of 5,464 eligible patients who underwent colonoscopies due to their symptoms in Asia.[@b14-cmar-10-3875] However, the prevalence of ACAs in alarm or non-alarm categories has not been explored in previous studies, creating a lack of data regarding this topic. Therefore, we further divided the symptomatic subgroup into alarm and non-alarm categories. No difference was determined between the prevalence of ACAs among patients in these two groups.

In this study, we further explored the distribution of ACAs stratified by anatomic location. There have been various discussions regarding the anatomic distribution of colorectal neoplasms. Proximal and distal colorectal neoplasms showed distinct epidemiological, clinical, and molecular characteristics.[@b15-cmar-10-3875] The finding of a proximal shift in ACAs was demonstrated in several previous studies.[@b4-cmar-10-3875],[@b16-cmar-10-3875],[@b17-cmar-10-3875] However, the study conducted by Friedenberg et al[@b18-cmar-10-3875] lacks the topic of proximal shift in the distribution of ACAs. Recently, Rondagh et al[@b19-cmar-10-3875] indicated that distal colorectal neoplasms are more likely to contain advanced histology than proximal colorectal neoplasms in a predominantly symptomatic population, which also corresponds with our findings. Prospective multicenter studies evaluating the proximal or distal shift of ACAs in large populations of Chinese subjects will be needed.

CRC is believed to evolve through the growth of polypoid adenoma over time.[@b20-cmar-10-3875] It is believed that ACAs can be classified according to the growth pattern by observing the location and morphology. These classifications have prognostic significance. For instance, nonpolypoid lesions appeared to indicate a worse prognosis than polypoid ones.[@b21-cmar-10-3875] However, nonpolypoid colorectal neoplasms (NP-CRNs) potentially explain the development of postcolonoscopy CRC. Soetikno et al[@b13-cmar-10-3875] show that NP-CRNs were more likely to contain carcinoma than polypoid lesions, regardless of size. Whether they represented a distinct disease with a pathogenetic pathway different from the typical adenoma--carcinoma sequence in colorectal tumorigenesis and had higher malignant potential remained a matter of debate. In this study, we found that nonpolypoid lesions have a higher proportion of ACAs in the symptomatic subgroup. It is important for endoscopists to be aware of the presence and clinical significance of these nonpolypoid polyps. It has been reported that one of the potential mechanisms underlying the difference in incidence and pathogenesis between nonpolypoid and polypoid lesions is genetic change, including Ki-ras mutations, p53 mutation, and frameshift mutations.[@b22-cmar-10-3875] Our results suggest that, in clinical practice, more attention should be given to nonpolypoid lesions since they appear to indicate worse prognosis than polypoid ones.

Limitations
===========

There were several limitations in this study. First, this was a single-center study with small sample size, and all the procedures were performed by the same endoscopist. Second, another potential issue is that the polyp size might be misjudged by the endoscopist.[@b23-cmar-10-3875] Due to the lack of standardization, the proportion of ACAs may not be accurately reflected in this study. A further limitation is the absence of data on the overall distribution of adenomas (advanced vs nonadvanced).

Conclusion
==========

In patients who underwent a colonoscopy because of their symptoms, the prevalence of ACAs was higher compared to the prevalence in patients who underwent the examination for screening or surveillance purposes. Additionally, more attention should be focused on the distal colon and nonpolypoid lesions to improve the detection rate of ACAs.
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###### 

Demographic and clinicopathological data of the study population

  Characteristics                              All            Indications for colonoscopy                 
  -------------------------------------------- -------------- ----------------------------- ------------- --------------
  Subjects                                     2,810          565                           813           1,432
  Age, years, mean (SD)                        59.8 (11.0)    56.7 (10.5)                   59.6 (10.1)   61.2 (11.9)
  Men, n (%)                                   1,533 (54.6)   301 (53.3)                    426 (52.4)    806 (56.3)
  BMI \>25, n (%)                              1,358 (48.3)   269 (47.6)                    398 (48.9)    692 (48.3)
  Family history of colorectal cancer, n (%)   238 (8.5)      46 (8.2)                      66 (8.1)      126 (8.8)
  Urban areas, n (%)                           2,172 (77.3)   436 (77.2)                    626 (77.0)    1,110 (77.5)
  Colorectal lesions, n                        1,285          223                           225           837

**Abbreviation:** BMI, body mass index.

###### 

Clinicopathological features of colorectal lesions analyzed in the study

  Features                                              Number
  ----------------------------------------------------- ------------------
  All colorectal lesions                                1,285
  Size, mm, mean (SD)                                   3--45, 6.7 (1.6)
  Morphology                                            
   Polypoid                                             822
   Nonpolypoid                                          463
  Location                                              
   Proximal colon                                       474
   Distal colon                                         811
  Pathological findings                                 
   Intramucosal carcinoma                               39
   Submucosal carcinoma                                 9
   Adenoma                                              675
   Hyperplastic polyp                                   546
   Others[a](#tfn2-cmar-10-3875){ref-type="table-fn"}   16

**Notes:**

There were eight hamartomatous polyps, one ectopic gastric mucosa, three granulation tissue, and four submucosal tumors.

###### 

Prevalence of ACAs in the subgroups

                                 Screening subgroup   Surveillance subgroup   Symptomatic subgroup
  ------------------------------ -------------------- ----------------------- ----------------------
  Patients                       565                  813                     1,432
  Total ACA number               34                   42                      184
  Number of patients with ACAs   23                   37                      157
  Prevalence of ACAs (%)         4.1                  4.6                     11.0

**Abbreviation:** ACA, advanced colorectal adenoma.

###### 

Distribution of ACAs and colorectal lesions stratified by anatomic location and morphological appearance into subgroups

  Subgroups               Lesion types         Location   Morphology         
  ----------------------- -------------------- ---------- ------------ ----- -----
  Screening subgroup      ACAs                 16         18           15    19
                          Colorectal lesions   86         137          129   94
  Surveillance subgroup   ACAs                 22         20           27    15
                          Colorectal lesions   95         130          123   102
  Symptomatic subgroup    ACAs                 53         131          111   73
                          Colorectal lesions   300        537          605   232

**Abbreviation:** ACA, advanced colorectal adenoma.

###### 

Proportion of ACAs in subgroups stratified by location

  Subgroups               Lesion types         Proximal    Distal       Distal vs proximal                
  ----------------------- -------------------- ----------- ------------ -------------------- ------------ -------
  Screening subgroup      ACAs (%)             16 (19.5)   18 (13.1)    0.66                 0.37--1.38   0.322
                          Colorectal lesions   86          137          --                   --           --
  Surveillance subgroup   ACAs (%)             22 (23.1)   20 (15.4)    0.60                 0.31--1.18   0.139
                          Colorectal lesions   95          130          --                   --           --
  Symptomatic subgroup    ACAs (%)             53 (17.7)   131 (24.4)   1.50                 1.05--2.15   0.024
                          Colorectal lesions   300         537          --                   --           --

**Abbreviation:** ACA, advanced colorectal adenoma.

###### 

Proportion of ACAs in subgroups stratified by morphology

  Subgroups               Types                Polypoid     Nonpolypoid   Nonpolypoid vs polypoid                
  ----------------------- -------------------- ------------ ------------- ------------------------- ------------ ---------
  Screening subgroup      ACAs (%)             15 (12.6)    19 (20.2)     1.93                      0.92--4.02   0.078
                          Colorectal lesions   129          94            --                        --           --
  Surveillance subgroup   ACAs (%)             27 (22.0)    15 (14.7)     0.61                      0.31--1.23   0.165
                          Colorectal lesions   123          102           --                        --           --
  Symptomatic subgroup    ACAs (%)             111 (18.3)   73 (31.5)     2.09                      1.48--2.94   \<0.001
                          Colorectal lesions   605          232           --                        --           --
